Insulin receptors purified from human placenta by sequential affinity chromatography on wheat germ lectin-agarose and insulin coupled to 1,1'-carbonyldiimidazoleactivated agarose (CDI-agarose) retained full binding activity but bound a greater than predicted amount of 17'I-labeled insulin-like growth factor I (IGF-I). IGF-I and multiplicationstimulating activity (MSA; the rat homologue of IGF-I) were equipotent in displacing either 125I-labeled IGF-I or 12I-labeled MSA from the purified receptors; insulin was 5-15 times more potent. Competitive binding studies indicated that this IGF binding activity could not be explained by cross-reaction with classical insulin receptors or by coelution of IGF-I or IGF-ll receptors. Instead, it was due to a minor population of discrete atypical insulin receptors (6-18% total insulin receptors) with moderately high affinity (Kd = 2-4 x 10-9 M) for IGF-I and MSA. These receptors were not an artifact of insulin-CD1-agarose chromatography, since they were present in wheat germ lectin-agarose-purified preparations and could also be purified from insulin-succinyldiaminodipropylamino-agarose.
Insulin receptors have been purified to homogeneity from human placental membranes by sequential affinity chromatography on wheat germ lectin-agarose and insulin covalently linked to succinyldiaminodipropylamino-agarose (1) . Using the same conditions of elution, but using an affinity resin consisting of insulin coupled to 1,1'-carbonyldiimidazoleactivated agarose (CDI-agarose), workers in our laboratory have also purified placental insulin receptors with full binding activity (6 nmol of insulin per mg of protein, equivalent to 2 mol of insulin per mol of receptor) comprised of subunits of Mr 130,000 (a) and Mr 90,000 (,8) (2) . However, since receptors for insulin-like growth factor I (IGF-I) in human placenta bind to wheat germ lectin-agarose (3), crossreact with insulin with -1/200th the affinity of insulin for its own receptor (4) , and have a similar subunit composition to the insulin receptor (3, (5) (6) (7) , we questioned whether these receptors might also be affinity-purified with insulin receptors. Initially, we found that receptors purified from insulin-CDI-agarose bound 125I-labeled IGF-I to a greater extent than predicted from the known crossreactivity of IGF-I with insulin receptors (8) . In the present report, this IGF-I binding activity is characterized and shown to be due to a distinct species of insulin receptor.
MATERIALS AND METHODS Materials. Porcine monocomponent insulin (Actrapid solution, 100 units/ml) was purchased from Novo (Copenhagen, Denmark). IGF-I was either purchased from Amgen (Thousand Oaks, CA), or was kindly provided by R. Humbel, Zurich (preparation I/4). Multiplication-stimulating activity (MSA; the rat homologue of IGF-II) was purified from the conditioned medium of BRL-3A rat liver cells as described (9) . Cohn fraction IV of human plasma (Commonwealth Serum Laboratories, Melbourne), acidified and subjected to cation exchange chromatography on SP Sephadex C-25 (10), was used as a source of IGFs for estimation of nonspecific binding. One microliter (-0.05% pure) contained the equivalent of 80 ng of IGF-I and 0.8 ng of insulin (determined by immunoassay). Insulin, Amgen IGF-I, and MSA were labeled with 125I by the fractional chloramine-T procedure (11) to specific activities of 100-130 ACi/ltg, 320-430 ACi/g, and 130-200 pCi/pg, respectively (1 Ci = 37 GBq), and purified by chromatography on cellulose CFII (11) . For some experiments (see legends to Figs. 2 and 5), 125I-labeled IGF-I was purified by hydrophobic interaction chromatography (12) on octyl-Sepharose CL-4B (Pharmacia).
Human immunoglobulin (Cohn fraction II) and Staphylococcus aureus [strain Cowan I, supplied as a formalin-fixed heat-killed 10o (wt/vol) suspension] were purchased from the Commonwealth Serum Laboratories (Melbourne); Triton X-100 and bovine serum albumin (RIA grade) were from Sigma; disuccinimidyl suberate and 1,1'-carbonyldiimidazole (CDI)-activated agarose [Reacti-Gel (6x)] were from Pierce; bovine serum albumin (Pentex) was from Miles; cellulose powder CFII was from Whatman; and polyethylene glycol 6000 (PEG) was from BDH. All reagents for NaDodSO4/ PAGE were from Bio-Rad Laboratories.
Antisera containing anti-receptor antibodies were from patients B-2 and B-10 with the type B syndrome of insulin resistance and acanthosis nigricans (13, 14) . Immunoglobulin G (IgG) was prepared from serum B-10 by affinity chromatography on protein A-Sepharose CL-4B (Pharmacia). Monoclonal antibodies to the insulin receptor (aIR-1) and to the IGF-I receptor (aIR-3) (7) were kindly donated by S. Jacobs (Wellcome). Rabbit antiserum to mouse immunoglobulins was purchased from Dakopatts (Denmark).
Insulin-CDI-agarose was prepared as described (2) . Insulin receptors with full binding activity were purified to homoAbbreviations: CDI-agarose, 1,1'-carbonyldiimidazole-activated agarose; IGF-I, insulin-like growth factor I; MSA, multiplicationstimulating activity.
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Affinity Labeling of Purified Receptors. Purified receptors at final protein concentrations of 300 and 600 ng/ml were incubated at 40C for 20 hr with 125I-labeled insulin (25 ng/ml) or 17-I-labeled MSA (5 ng/ml), respectively, in the presence or absence of excess unlabeled hormones in 0.1 M sodium phosphate buffer containing Triton X-100 (0.1 g per 100 ml) and bovine serum albumin (1.0 g per 100 ml). Disuccinimidyl suberate, freshly dissolved in'dimethyl sulfoxide (100 mM) was added to a final concentration of 1 mM. After 15 min at 00C, 50-,ul aliquots were boiled for 5 min with equal volumes of twice concentrated NaDodSO4/PAGE sample buffer containing 0.1 M dithiothreitol, and subjected to NaDodSO4/ PAGE and autoradiography as reported (16) .
RESULTS
Bitding Studies with Ainity-Purified Receptors. Elution profiles from the insulin-CDI-agarose column for 125I-labeled IGF-I and 1251-labeled insulin binding activities were identical. Specific binding at 125I-labeled IGF-I and 125I-labeled insulin, expressed as bound/free per 100 ng of protein, ranged from 0.07 to 0.26 and from 0.50 to 1.02, respectively. In the same preparations of purified receptor, the specific binding of 2"I-labeled IGF-I was ¼4th-Yl4th that for 125I-labeled insulin-i.e., 7-25 times higher than predicted from 1% crossreactivity with the insulin receptor.
To resolve the identity of the IGF-I binding activity copurifying with insulin receptors, competition binding studies were performed with insulin, IGF-I, and MSA ( Fig. 1 sites was only 11% ± 5% (mean ± SD) of the total insulin binding sites (Fig. 2) . Fig. 3, or 30 Ml of pooled neutralized insulin-CDI-agarose eluate. The latter (10 ml, 1.5 Mg/ml) was derived from 8 ml of wheat germ lectin-agarose eluate (0.7 mg/ml). The relative potencies of the three unlabeled peptides in competing for specifically bound 1251_ labeled insulin were the same regardless of whether the receptors were eluted from wheat germ lectin-agarose or insulin-CDI-agarose.
Immunological Properties of the Atypical Insulin Receptor: Comparison with Classical Insulin and IGF-I Receptors. Receptors from the insulin affinity column, labeled with 125i-labeled insulin (>90% classical insulin receptors), were precipitated completely by antisera B-2 and B-10, while classical IGF-I receptors not bound to the column, labeled with 125I-labeled IGF-I, were only 25% precipitated by antiserum B-2 and not at all by antiserum B-10. Intermediate reactivity was shown by the 1251-labeled IGF-I-labeled sites eluting from the column (atypical insulin receptors): 46% precipitation with antiserum B-2 and 22% with antiserum B-10 (Fig. 5) .
The reactivity of the monoclonal antibodies with the classical insulin and IGF-I receptors was predictable (7, 18) : IR-1 precipitated 45% of affinity-purified 1251-labeled insulinlabeled receptors and an insignificant proportion (<3%) of the classical IGF-I receptors in the unbound fraction. aIR-3 inhibited 1251-labeled IGF-I binding to classical IGF-I receptors by 78% and had no effect on 125I-labeled insulin binding. (Fig. 1) , 125I-labeled MSA would be more likely to detect IGF-II receptors, if present (6, 17) . When subjected to NaDodSO4/PAGE under reducing conditions, chemically crosslinked 125I-labeled MSA appeared as a Mr 140,000 complex, as did crosslinked 12 I_ labeled insulin (Fig. 6 ). Under nonreducing conditions, both labeled hormones migrated as Mr 280,000, 300,000, and 330,000 complexes (data not shown). The autoradiographic intensity of the bands was significantly diminished by unlabeled insulin, and to a lesser extent by IGF-I and MSA (Fig. 6) . In contrast, classic IGF-II receptors, after covalent labeling with _25I-labeled MSA, are resolved as Mr 260,000 complexes in reduced gels and as Mr 220,000 complexes in nonreduced gels (6, 17) .
Are Atypical Insulin Receptors an Artifact of Affinity Chromatography on Insulin-CDI-Agarose? When insulin coupled to succinyldiaminodipropylamino-agarose (1) was used, and competition binding studies with 125I-labeled IGF-I and increasing concentrations of insulin, IGF-I, and MSA were performed on the eluate and unbound fractions, the results were the same as those obtained using insulin-CDI-agarose. This indicates that the CDI-agarose matrix'per se was not responsible for the appearance of atypical insulin receptors in the column eluates. The procedures associated with insulin affinity chromatography did not appear to generate atypical insulin receptors because these receptors were also present in wheat germ lectin-agarose-purified preparations. Most of the I251-labeled MSA binding activity in the latter could be ascribed to atypical insulin receptors rather than to crossreaction With classical insulin, IGF-I, or IGF-II receptors. First, in a representative experiment, 125I-labeled MSA binding (16% per 12 Ag) was too high to be explained by crossreaction with insulin and/or IGF-I receptors (1251-labeled insulin binding and '25I-labeled IGF-I binding each being 42%). Second, 1251-labeled MSA binding to glycoproteins purified from wheat germ lectin-agarose was displaced by unlabeled insulin, IGF-I, and MSA in that order of potency and could be precipitated by antiserum B-10 IgG (30% at a final IgG concentration of 14 pug/ml). Finally, affinity crosslinking of I251-labeled MSA to these glycoproteins revealed M -140,000 reduced complexes and not the Mr 260,000 monomers characteristic of the IGF-II receptor (data not shown).
DISCUSSION
The IGF-I binding activity copurifying with human placental insulin receptors can be ascribed to a small discrete population of atypical insulin receptors with moderate affinity for the insulin-like growth factors, IGF-I and MSA. It is not explained by crossreaction with classical insulin receptors or coelution of IGF-I or IGF-II receptors. It is likely that these atypical insulin receptors are the same as the type III IGF receptors detected by Hintz and colleagues (19) on human IM-9 lymphocytes and human placental membranes by virtue of their specific 125I-labeled IGF-II binding, which was displaced almost equipotently by insulin, IGF-I, and IGF-II (19). Werther et al. (20) had noted earlier that specific I251-labeled IGF-II binding to IM-9 lymphocytes was displaced far more readily by unlabeled insulin than by the IGFs.
Although the atypical insulin receptors are distinct, they share many of the features of the insulin and IGF-I receptors.
Their affinity for IGF-I is moderately high (Kd = 2-4 x 10-9 M) but Y2-'/3rd that of the IGF-I receptors (Fig. 2) . Insulin is 5-15 times more potent than IGF-I in displacing 125I-labeled IGF-I from these sites (Fig. 1) , indicating a high affinity for insulin (Kd = 0.2-0.6 x 10-9 M). They display intermediate reactivity toward polyclonal and monoclonal antibodies to the insulin and IGF-I receptors (Fig. 5 ) and have the same subunit structure as the insulin and IGF-I receptors (Fig. 6) .
Like the IGF-I receptors in solubilized human placental membranes (16) and in the unbound fraction from the insulin affinity column (Fig. 5) , only part of the 1251-labeled IGF-I bound to atypical insulin receptors could be precipitated by antiserum B-2. Similar results were obtained by using antiserum B-10 (Fig. 5) . Thus, the atypical receptors must also contain subpopulations of receptors not recognized by these antisera. These receptors would contribute to a small degree to the two types of IGF-I binding sites present in solubilized human placental membranes and delineated on the basis of their immunoreactivity with antiserum B-2 (16) . Since disulfide reduction of human placental IGF-I receptors results in the conversion of B-2 reactive receptors to B-2 nonreactive receptors (24), a similar mechanism could be invoked for the existence of B-2 nonreactive atypical insulin receptors.
Amino-terminal sequences have been obtained for both the chromatography on a monoclonal antibody column (23) . The latter preparation was reportedly contaminated by up to 20% with IGF-I receptors (22) . Since atypical insulin receptors coelute with insulin receptors from insulin affinity columns and show more immunological relatedness to insulin receptors than to IGF-I receptors, it is likely that they contaminate purified receptor preparations and, in fact, account for the IGF-I receptors noted by Ebina et al. (22) . cDNA probes for the insulin receptor gave multiple hybridization bands on RNA blot analysis (21, 22) . These different mRNAs may represent modifications of the same gene (variable splicing, varying lengths of 3' of 5' untranslated sequences) but might also represent homologous genes, including one for the atypical insulin receptor. Also, since the nucleotide sequences for both reported receptor cDNAs are slightly different (21, 22) , they could conceivably correspond to cDNA clones for the insulin receptor and the atypical insulin receptor.
